Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Nutex Health Inc. securities, alleging misleading statements and fraudulent activities during the Class Period from August 8, 2024, to August 14, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Nutex Health Inc. made false and misleading statements regarding its financial practices and internal controls, particularly related to its engagement with HaloMD, a third-party vendor [5]. - Allegations include that Nutex's revenues from HaloMD were unsustainable due to fraudulent conduct, and that the company overstated its ability to remediate internal control weaknesses [5]. - The lawsuit asserts that Nutex improperly classified stock-based compensation obligations, which increased the risk of failing to file timely financial reports with the SEC [5]. Group 2: Class Action Participation - Investors who purchased Nutex securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by submitting a form or contacting the law firm directly [3][6]. - A lead plaintiff is needed to represent the class, and interested individuals must move the Court by October 21, 2025 [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions for investors [4]. - Founding partner Laurence Rosen has received recognition as a leading figure in the plaintiffs' bar, further establishing the firm's credibility [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased SelectQuote, Inc. securities between September 9, 2020, and May 1, 2025, of the upcoming lead plaintiff deadline on October 10, 2025, for a class action lawsuit [1] Group 1: Class Action Details - Investors who bought SelectQuote securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2] - The lead plaintiff must file a motion with the Court by October 10, 2025, to represent other class members [2] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [3] Group 3: Allegations Against SelectQuote - The lawsuit alleges that SelectQuote made false and misleading statements and failed to disclose critical information regarding its business practices, including directing Medicare beneficiaries to insurers that compensated SelectQuote the most [4] - It is claimed that SelectQuote did not provide unbiased comparisons for Medicare Advantage plans and received illegal kickbacks, leading to potential regulatory and legal sanctions [4] - The misleading statements from SelectQuote resulted in investor damages when the true nature of the company's practices became known [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Altimmune, Inc. securities between August 10, 2023, and June 25, 2025, about the October 6, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - A class action lawsuit has been filed against Altimmune, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - To participate in the class action, investors can submit a form or contact the law firm for more information [2][5] - The lawsuit claims that Altimmune misrepresented the results of its IMPACT Phase 2b MASH trial, leading to investor damages when the true results were revealed [4] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [3] - The firm has been consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [3] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in litigation [3]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Spectrum Pharmaceuticals, Inc. during the specified class period of the upcoming lead plaintiff deadline on September 24, 2025, as the lead plaintiff process has been reopened by the Court [1]. Group 1: Class Action Details - Investors who purchased Spectrum Pharmaceuticals common stock between May 12, 2022, and September 22, 2022, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed against Spectrum Pharmaceuticals, and interested parties must move the Court to serve as lead plaintiff by the September 24, 2025 deadline [3]. - The lawsuit alleges that Spectrum made false or misleading statements regarding its PINNACLE Study, which involved the drug poziotinib for treating certain lung cancer patients, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding purchasers of common units of XPLR Infrastructure, LP (formerly Nextera Energy Partners, LP) about a class action lawsuit and the upcoming lead plaintiff deadline on September 8, 2025 [1]. Group 1: Class Action Details - Investors who purchased XPLR common units between September 27, 2023, and January 27, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lead plaintiff must file a motion with the Court by September 8, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, and many attorneys at the firm have received accolades from Lawdragon and Super Lawyers [4]. Group 3: Case Allegations - The lawsuit alleges that during the class period, XPLR made false and misleading statements regarding its operations as a yieldco, struggling to maintain operations and downplaying risks associated with financing arrangements [5]. - It is claimed that XPLR could not resolve its financing issues without risking significant unitholder dilution and planned to halt cash distributions to redirect funds to resolve these financings [5]. - The lawsuit asserts that the yieldco business model and distribution growth rate were unsustainable, leading to materially false and misleading public statements by the defendants [5].

Core Viewpoint - A class action lawsuit has been filed against Snap Inc. for misleading investors regarding its advertising revenue and growth potential during the specified Class Period from April 29, 2025, to August 5, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Snap's management created a false impression of reliable advertising revenue and growth while downplaying macroeconomic instability [5]. - It is alleged that Snap's optimistic reports did not reflect the reality of its operational challenges, leading to investor damages when the truth was revealed [5]. Group 2: Participation Information - Investors who purchased Snap securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 alone [4]. - The firm has been recognized for its success in securities class action settlements and has a history of representing investors globally [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Novo Nordisk A/S securities between May 7, 2025, and July 28, 2025, of the September 30, 2025, deadline to become lead plaintiffs in a class action lawsuit [1] Group 1: Class Action Details - A class action lawsuit has been filed against Novo Nordisk, and investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - Investors wishing to serve as lead plaintiffs must file a motion with the Court by September 30, 2025 [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] Group 3: Case Allegations - The lawsuit alleges that Novo Nordisk provided misleading statements about its growth potential while concealing material adverse facts [4] - It is claimed that the company overstated its potential in the GLP-1 market and the likelihood of patients switching to its branded alternatives, leading to investor damages when the truth was revealed [4]

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between November 7, 2024 and July 8, 2025, both dates inclusive (the “Class Period”, of the important September 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased RxSight securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Fiserv, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the Fiserv common stock is from July 24, 2024, to July 22, 2025, inclusive [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A lead plaintiff must file a motion with the Court by September 22, 2025, to represent other class members [2] Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has consistently ranked in the top 4 for securities class action settlements since 2013, recovering hundreds of millions for investors [3] Group 3: Case Allegations - The lawsuit alleges that Fiserv made false and misleading statements regarding its Clover platform and the forced migration of Payeezy merchants [4] - It is claimed that Clover's revenue growth was artificially inflated due to these forced conversions, masking a slowdown in new merchant business [4] - The lawsuit asserts that many former Payeezy merchants switched to competitors due to Clover's high pricing and compatibility issues, leading to a significant slowdown in Clover's growth [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Petco Health and Wellness Company, Inc. securities between January 14, 2021, and June 5, 2025, of the upcoming lead plaintiff deadline on August 29, 2025, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Petco securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by August 29, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that Petco made false and misleading statements regarding the sustainability of its pandemic-related growth and the viability of its business model focused on premium pet food [5]. - It is claimed that the strength of Petco's product strategy was overstated, and the company downplayed the severity of issues affecting its business [5]. - The lawsuit asserts that these misrepresentations led to investor damages when the true situation was revealed [5].